⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4674542 | 1.00 | — | — | |
| SCHEMBL3896054 | 0.88 | ALDH1A1 (0.46) | — | |
| SCHEMBL3897207 | 0.86 | GPR119 (0.50) | — | |
| SCHEMBL23127108 | 0.81 | — | — | |
| SCHEMBL19043861 | 0.80 | KDM2B (0.33) | — | |
| SCHEMBL3442139 | 0.79 | ALDH1A1 (0.52) | — | |
| SCHEMBL3442137 | 0.79 | ALDH1A1 (0.52) | — | |
| SCHEMBL3442633 | 0.79 | ALDH1A1 (0.52) | — | |
| SCHEMBL20292998 | 0.78 | — | — | |
| SCHEMBL6796734 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519393-B1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | EPIZYME INC (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-2791139-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | Dr Reddys Laboratories Ltd (IN) | 2017-11-08 | — | — | EP | disclosed |
| US-9289419-B2 | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-03-22 | — | — | US | disclosed |
| US-20150164869-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-06-18 | — | — | US | disclosed |
| US-9045479-B2 | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-06-02 | — | — | US | disclosed |
| US-20150005280-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-01-01 | — | — | US | disclosed |
| EP-2791139-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | Dr. Reddy's Laboratories Ltd. (IN) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088257-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-06-20 | — | — | WO | disclosed |
| US-7557215-B2 | Anthraquinone compounds as anti cancer compounds | SOMANTA LIMITED (GB) | 2009-07-07 | — | — | US | disclosed |
| EP-1701939-B1 | ANTHRAQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS | SOMANTA LTD (GB) | 2009-02-25 | — | — | EP | disclosed |
| EP-1453501-B1 | N- ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORP (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008062252-A1 | N-OXIDES OF CYTOTOXIC ANTHRAQUINONES AS HYPOXIA-TARGETING PRODRUGS IN CANCER TREATMENT | ACCESS PHARMACEUTICALS, INC (US) | 2008-05-29 | — | — | WO | disclosed |
| US-7348328-B2 | MCH antagonists for the treatment of obesity | SCHERING CORPORATION (US) | 2008-03-25 | — | — | US | disclosed |
| US-20080027107-A1 | Antharquinone Compounds as Anti Cancer Compounds | SOMANTA LIMITED (GB) | 2008-01-31 | — | — | US | disclosed |
| EP-1701939-A1 | ANTHRAQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS | Somanta Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005061453-A1 | ANTHARQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS | SOMANTA LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
| EP-1453501-A1 | N- ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040122017-A1 | MCH antagonists for the treatment of obesity | SCHERING CORPORATION | 2004-06-24 | — | — | US | disclosed |
| WO-2003047568-A1 | N-ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |